Document is current
Any future updates will be listed below
-
Authors
García-Valverde, Alfonso
Rosell, Jordi
Sayols, Sergi https://orcid.org/0000-0002-3877-4170
Gómez-Peregrina, David
Pilco-Janeta, Daniel F. https://orcid.org/0000-0003-3640-0498
Olivares-Rivas, Iván
de Álava, Enrique
Maurel, Joan
Rubió-Casadevall, Jordi
Esteve, Anna
Gut, Marta
Valverde, Claudia
Barretina, Jordi
Carles, Joan
Demetri, George D.
Fletcher, Jonathan A.
Arribas, Joaquín https://orcid.org/0000-0002-0504-0664
Serrano, César https://orcid.org/0000-0003-1416-8739
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FI20/00275, PT17/0009/0019)
PhD fellowship from the National Secretary for Higher Education, Science, Technology and Innovation of Ecuador
Co-funded by FEDER
- License Information
-
More Information
Article History
Received: 22 July 2021
Revised: 20 September 2021
Accepted: 28 September 2021
First Online: 7 October 2021
Competing interests
: SS has received consulting fees (advisory role) from Boehringer Ingelheim. DFP-J has received travel grants from Pfizer, Roemmers, and Roche. MG has received consulting fees from Roche and Illumina. CV has received consulting fees (advisory role) from Lilly, PharmaMar, Pfizer, Eisai, Bayer, Mundipharma, GlaxoSmithKline, and travel grants from PharmaMar, Lilly, Novartis, Bayer, and Pfizer. CS has received research funding (institution) from Karyopharm, Pfizer, Inc, Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from Bayer AG and Blueprint Medicines; and travel grants from PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly. The remaining authors declare no competing interests.
